Oxford Pharmascience has undertaken a £20m equity capital raise as it continues to make progress with its NSAID portfolio. The placing is significantly higher than its initial target of £5m, enabling the group to further develop its product portfolio and investigate additional potential applications for its technology. OXPzeroTM Naproxen continues to progress having recently achieved bioequivalence and commenced its endoscopy pilot clinical trial. The development of a chewable OXPzeroTM ibuprofe ....
